Egetis Therapeutics AB (LTS:0ABW) Net Income (Continuing Operations) : kr-319.40 Mil (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Egetis Therapeutics AB Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Egetis Therapeutics AB's Net Income (Continuing Operations) for the three months ended in Sep. 2024 was kr-86.30 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-319.40 Mil.

Egetis Therapeutics AB Net Income (Continuing Operations) Historical Data

The historical data trend for Egetis Therapeutics AB's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Net Income (Continuing Operations) Chart

Egetis Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-61.42

-178.02

-104.50

-193.80

-326.90

Egetis Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-86.30	-86.20	-75.00	-71.90	-86.30

Egetis Therapeutics AB Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-319.40 Mil.

Egetis Therapeutics AB (LTS:0ABW) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Egetis Therapeutics AB Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Egetis Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (LTS:0ABW) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

EGTX:Sweden P0F:Germany

Address

Grev Turegatan 11 C, Stockholm, SWE, 114 46

Website

https://www.egetis.com

Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines